Ogilvie syndrome risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ogilvie syndrome}} | {{Ogilvie syndrome}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AEL}} | ||
==Overview== | ==Overview== | ||
Common risk factors of Ogilvie's syndrome include having [[Neurological disease|neurologic disorders]], taking [[Narcotic|narcotic medications]], and [[trauma]]. Other risk factors include [[systemic lupus erythematosus]], [[alcoholism]], and [[multiple myeloma]]. | |||
==Risk Factors== | ==Risk Factors== | ||
* Having cerebral palsy or other nervous system (neurologic) disorders | Common risk factors for Ogilvie's syndrome include the following:<ref name="AoS">[http://archsurg.ama-assn.org/cgi/content/abstract/135/6/682 Ogilvie Syndrome as a Postoperative Complication] Patty L. Tenofsky, MD; R. Larry Beamer, MD; R. Stephen Smith, MD [http://archsurg.ama-assn.org/ Arch Surg.] 2000;135:682-687.</ref><ref name="pmid28257284">{{cite journal| author=Sreter KB, Barisic B, Popovic-Grle S| title=Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
. | journal=Int J Clin Pharmacol Ther | year= 2017 | volume= 55 | issue= 5 | pages= 442-448 | pmid=28257284 | doi=10.5414/CP202784 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28257284 }}</ref> | ||
* | * Having [[cerebral palsy]] or other nervous system [[Neurological disease|(neurologic) disorders]] | ||
* | * Taking [[Narcotic|narcotic medications]] | ||
* [[Trauma]] | |||
* Cardiac diseases as [[myocardial infarction]] | |||
Less common risk factors for Ogilvie's syndrome include the following:<ref name="pmid25170234">{{cite journal| author=García López CA, Laredo-Sánchez F, Malagón-Rangel J, Flores-Padilla MG, Nellen-Hummel H| title=Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge. | journal=World J Gastroenterol | year= 2014 | volume= 20 | issue= 32 | pages= 11443-50 | pmid=25170234 | doi=10.3748/wjg.v20.i32.11443 | pmc=4145788 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25170234 }}</ref> | |||
* [[Systemic lupus erythematosus]] | |||
* [[Alcoholism]] | |||
* [[Multiple myeloma]] | |||
* [[Systemic sclerosis]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 16:44, 8 February 2018
| Ogilvie syndrome Microchapters
|
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ogilvie syndrome risk factors On the Web |
|
American Roentgen Ray Society Images of Ogilvie syndrome risk factors |
|
Risk calculators and risk factors for Ogilvie syndrome risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Common risk factors of Ogilvie's syndrome include having neurologic disorders, taking narcotic medications, and trauma. Other risk factors include systemic lupus erythematosus, alcoholism, and multiple myeloma.
Risk Factors
Common risk factors for Ogilvie's syndrome include the following:[1][2]
- Having cerebral palsy or other nervous system (neurologic) disorders
- Taking narcotic medications
- Trauma
- Cardiac diseases as myocardial infarction
Less common risk factors for Ogilvie's syndrome include the following:[3]
References
- ↑ Ogilvie Syndrome as a Postoperative Complication Patty L. Tenofsky, MD; R. Larry Beamer, MD; R. Stephen Smith, MD Arch Surg. 2000;135:682-687.
- ↑ Sreter KB, Barisic B, Popovic-Grle S (2017). "Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome". Int J Clin Pharmacol Ther. 55 (5): 442–448. doi:10.5414/CP202784. PMID 28257284.
- ↑ García López CA, Laredo-Sánchez F, Malagón-Rangel J, Flores-Padilla MG, Nellen-Hummel H (2014). "Intestinal pseudo-obstruction in patients with systemic lupus erythematosus: a real diagnostic challenge". World J Gastroenterol. 20 (32): 11443–50. doi:10.3748/wjg.v20.i32.11443. PMC 4145788. PMID 25170234.